Precision BioSciences, Inc.: Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company
Source: finanznachrichten.de